The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Pivotal findings at ASH 2020
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, shares some of his highlights from ASH 2020. In particular, Prof. Tam discusses encouraging updated results from the CAPTIVATE chronic lymphocytic leukemia (CLL) trial (NCT02910583) of ibrutinib plus venetoclax. This trial found that patients who achieve confirmed measurable residual disease (MRD) negativity after 12 months can discontinue treatment and expect a durable progression-free survival. Additionally, evidence of feasibility of chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma was a promising finding featured at ASH 2020. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Prof. Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, has received honoraria from Beigene, Janssen and AbbVie.
